The evolving role of gene-based treatment in surgery

British Journal of Surgery

Volumn 92, Issue 12, 2005, Pages 1466-1480

  Tan, P H ^a,b   Chan, C L H ^c   Chan, C ^b,d   George, A J T ^b  

^a STOKE MANDEVILLE HOSPITAL   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALLOVECTIN 7; ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE; BETA 2 MICROGLOBULIN; BRCA1 PROTEIN; CANCER VACCINE; CN 706; CYTOCHROME P450; CYTOKINE; CYTOSINE DEAMINASE; DENDRITIC CELL VACCINE; DRUG CARRIER; E1A PROTEIN; EARLY GROWTH RESPONSE FACTOR 1; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA B7 ANTIGEN; IMMUNOSUPPRESSIVE AGENT; MAJOR HISTOCOMPATIBILITY ANTIGEN; MULTIDRUG RESISTANCE PROTEIN 1; OLIGODEOXYNUCLEOTIDE; ONCOLYTIC VIRUS VACCINE; PARVOVIRUS VECTOR; PLASMID DNA; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53; RETROVIRUS VECTOR; SMALL INTERFERING RNA; THYMIDINE KINASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VIRUS VACCINE; VIRUS VECTOR;

ACUTE GRAFT REJECTION; ANGINA PECTORIS; ANTIGEN PRESENTING CELL; ARTERY INTIMA PROLIFERATION; ASTROCYTOMA; BLADDER CANCER; BONE MARROW DEPRESSION; BREAST CANCER; BUERGER DISEASE; CANCER CHEMOTHERAPY; CHRONIC GRAFT REJECTION; CLINICAL TRIAL; COLON CARCINOMA; COLORECTAL CARCINOMA; CYTOTOXICITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; ESOPHAGUS CARCINOMA; FUNCTIONAL GENOMICS; GENE SEQUENCE; GENE THERAPY; GENE TRANSFER; GENETIC ENGINEERING; GENETIC TRANSFECTION; GLIOBLASTOMA; GRAFT FAILURE; HEAD CANCER; HEART SURGERY; HUMAN; HUMAN GENOME; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INTESTINE CANCER; KIDNEY CARCINOMA; LEG ISCHEMIA; LEUKEMOID REACTION; LIVER CANCER; LIVER CELL CARCINOMA; LIVER METASTASIS; MEDLINE; MELANOMA; MESOTHELIOMA; METASTASIS; NECK CANCER; NEUROSURGERY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; ORTHOPEDIC SURGERY; OSTEOSARCOMA; OVARY CANCER; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW; SARCOMA; SIDE EFFECT; SKIN METASTASIS; SUICIDE GENE THERAPY; SURGEON; SURGICAL TECHNIQUE; THORAX SURGERY; UROLOGIC SURGERY; VASCULAR SURGERY; VIRAL GENE DELIVERY SYSTEM;

DRUG RESISTANCE; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNOTHERAPY; NEOPLASMS; NERVOUS SYSTEM DISEASES; ORTHOPEDIC PROCEDURES; SURGICAL PROCEDURES, OPERATIVE; THORACIC SURGICAL PROCEDURES; TRANSPLANTATION; UROLOGIC SURGICAL PROCEDURES; VASCULAR SURGICAL PROCEDURES;

EID: 28944434709     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1002/bjs.5181     Document Type: Review

References (149)

1. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J et al. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860-921.
2. Rogers S. Reflections on issues posed by recombinant DNA molecule technology. II. In: Ethical and Scientific Issues Posed by Human Uses of Molecular Genetics, Lappe M, Morison RS (eds). New York Academy of Sciences: New York, 1976; 66-70.
3. Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 1995; 270: 475-480.
4. Goldfarb DS, Gariepy J, Schoolnik G, Kornberg RD. Synthetic peptides as nuclear localization signals. Nature 1986; 322: 641-644.
5. Rayner SA, Larkin DF, George AJ. TNF receptor secretion after ex vivo adenoviral gene transfer to cornea and effect on in vivo graft survival. Invest Ophthalmol Vis Sci 2001; 42: 1568-1573.
6. Tan PH, Beutelspacher SC, Xue SA, Wang YH, Mitchell P, McAlister JC et al. Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy. Blood 2005; 105: 3824-3832.
7. Mann MJ, Gibbons GH, Hutchinson H, Poston RS, Hoyt EG, Robbins RC et al. Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues. Proc Natl Acad Sci U S A 1999; 96: 6411-6416.
8. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999; 6: 1258-1266.
9. Yang NS, Sun WH. Gene gun and other non-viral approaches for cancer gene therapy. Nat Med 1995; 1: 481-483.
10. Pillai R, Petrak K, Blezinger P, Deshpande D, Florack V, Freimark B et al. Ultrasonic nebulization of cationic lipid-based gene delivery systems for airway administration. Pharm Res 1998; 15: 1743-1747.
11. Aihara H, Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 1998; 16: 867-870.
12. Feigner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci U S A 1987; 84: 7413-7417.
13. Tan PH, King WJ, Chen D, Awad HM, Mackett M, Lechler RI et al. Transferrin receptor-mediated gene transfer to the corneal endothelium. Transplantation 2001; 71: 552-560.
14. Tan PH, Manunta M, Ardjomand N, Xue SA, Larkin DFP, Haskard DO et al. Antibody targeted gene transfer to endothelium. J Gene Med 2003; 5: 311-323.
15. Arancibia-Carcamo CV, Oral HB, Haskard DO, Larkin DF, George AJ. Lipoadenofection-mediated gene delivery to the corneal endothelium: prospects for modulating graft rejection. Transplantation 1998; 65: 62-67.
16. Hoffman M. Gene therapy. New vector puts payload on the outside. Science 1992; 256: 445.
17. Klatzmann D. Gene therapy for metastatic malignant melanoma: evaluation of tolerance to intratumoral injection of cells producing recombinant retroviruses carrying the herpes simplex virus type 1 thymidine kinase gene, to be followed by ganciclovir administration. Hum Gene Ther 1996; 7: 255-267.
18. Link CJ Jr, Moorman D, Seregina T, Levy JP, Schabold KJ. A phase I trial of in vivo gene therapy with the herpes simplex thymidine kinase/ganciclovir system for the treatment of refractory or recurrent ovarian cancer. Hum Gene Ther 1996; 7: 1161-1179.
19. Crystal RG, Hirschowitz E, Lieberman M, Daly J, Kazam E, Henschke C et al. Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the prodrug 5-fluorocytosine. Hum Gene Ther 1997; 8: 985-1001.
20. Lohr M, Hoffmeyer A, Kroger J, Freund M, Hain J, Holle A et al. Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. Lancet 2001; 357: 1591-1592.
21. Pandha HS, Martin LA, Rigg A, Hurst HC, Stamp GW, Sikora K et al. Genetic prodrug activation therapy for breast cancer: a phase I clinical trial of erbB-2-directed suicide gene expression. J Clin Oncol 1999; 17: 2180-2189.
22. Hank JA, Robinson RR, Surfus J, Mueller BM, Reisfeld RA, Cheung NK et al. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res 1990; 50: 5234-5239.
23. Cascinelli N, Foa R, Parmiani G, Arienti F, Belli F, Bernengo MG et al. Active immunization of metastatic melanoma patients with interleukin-4 transduced, allogeneic melanoma cells. A phase I-II study. Hum Gene Ther 1994; 5: 1059-1064.
24. Moller P, Sun Y, Dorbic T, Alijagic S, Makki A, Jurgovsky K et al. Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study. Br J Cancer 1998; 77: 1907-1916.
25. Kang WK, Park C, Yoon HL, Kim WS, Yoon SS, Lee MH et al. Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. Hum Gene Ther 2001; 12: 671-684.
26. Seigler HF, Darrow TL, Abdel-Wahab Z, Gangavalli R, Barber J. A phase I trial of human gamma interferon transduced autologous tumor cells in patients with disseminated malignant melanoma. Hum Gene Ther 1994; 5: 761-777.
27. Chang AE, Li Q, Bishop DK, Normolle DP, Redman BD, Nickoloff BJ. Immunogenetic therapy of human melanoma utilizing autologous tumor cells transduced to secrete granulocyte-macrophage colony-stimulating factor. Hum Gene Ther 2000; 11: 839-850.
28. Heslop HE, Ng CY, Li C, Smith CA, Loftin SK, Krance RA et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996; 2: 551-555.
29. Rubin J, Galanis E, Pitot HC, Richardson RL, Burch PA, Charboneau JW et al. Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7. Gene Ther 1997; 4: 419-425.
30. Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE, Kipps TJ. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 2000; 96: 2917-2924.
31. Schoof DD, Smith JW II, Disis ML, Brant-Zawadski P, Wood W, Doran T et al. Immunization of metastatic breast cancer patients with CD80-modified breast cancer cells and GM-CSF. Adv Exp Med Biol 1998; 451: 511-518.
32. Sobol RE, Shawler DL, Carson C, Van Beveren C, Mercola D, Fakhrai H et al. Interleukin 2 gene therapy of colorectal carcinoma with autologous irradiated tumor cells and genetically engineered fibroblasts: a phase I study. Clin Cancer Res 1999; 5: 2359-2365.
33. Tartour E, Mehtali M, Sastre-Garau X, Joyeux I, Mathiot C, Pleau JM et al. Phase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours: clinical and immunological findings. Br J Cancer 2000; 83: 1454-1461.
34. Arienti F, Belli F, Napolitano F, Sule-Suso J, Mazzocchi A, Gallino GF et al. Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells. Hum Gene Ther 1999; 10: 2907-2916.
35. Jaffee EM, Abrams R, Cameron J, Donehower R, Duerr M, Gossett J et al. A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma. Hum Gene Ther 1998; 9: 1951-1971.
36. Hui KM, Ang PT, Huang L, Tay SK. Phase I study of immunotherapy of cutaneous metastases of human carcinoma using allogeneic and xenogeneic MHC DNA-liposome complexes. Gene Ther 1997; 4: 783-790.
37. Stewart AK, Lassam NJ, Quirt IC, Bailey DJ, Rotstein LE, Krajden M et al. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial. Gene Ther 1999; 6: 350-363.
38. Schmidt-Wolf IG, Huhn D, Neubauer A, Wittig B. Interleukin-7 gene transfer in patients with metastatic colon carcinoma, renal cell carcinoma, melanoma, or with lymphoma. Hum Gene Ther 1994; 5: 1161-1168.
39. Lotze MT, Zitvogel L, Campbell R, Robbins PD, Elder E, Haluszczak C et al. Cytokine gene therapy of cancer using interleukin-12: murine and clinical trials. Ann N Y Acad Sci 1996; 795: 440-454.
40. Nemunaitis J, Fong T, Robbins JM, Edelman G, Edwards W, Paulson RS et al. Phase I trial of interferon-gamma (IFN-gamma) retroviral vector administered intratumorally to patients with metastatic melanoma. Cancer Gene Ther 1999; 6: 322-330.
41. Kusumoto M, Umeda S, Ikubo A, Aoki Y, Tawfik O, Oben R et al. Phase 1 clinical trial of irradiated autologous melanoma cells adenovirally transduced with human GM-CSF gene. Cancer Immunol Immunother 2001; 50: 373-381.
42. Nabel GJ, Gordon D, Bishop DK, Nickoloff BJ, Yang ZY, Aruga A et al. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci U S A 1996; 93: 15 388-15 393.
43. Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995; 345: 9-11.
44. Mastrangelo MJ, Maguire HC Jr, Eisenlohr LC, Laughlin CE, Monken CE, McCue PA et al. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 1999; 6: 409-422.
45. Galanis E, Hersh EM, Stopeck AT, Gonzalez R, Burch P, Spier C et al. Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience. J Clin Oncol 1999; 17: 3313-3323.
46. Gilly FN, Sayag-Beaujard AC, Bienvenu J, Aymard M, Touraine-Moulin F, Favrot M et al. Gene therapy with AdV-IL2 (TG 1021) in unresectable digestive adenocarcinoma. Phase I-II study, first inclusions. Adv Exp Med Biol 1998; 451: 527-530.
47. Stopeck AT, Jones A, Hersh EM, Thompson JA, Finucane DM, Gutheil JC et al. Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma. Clin Cancer Res 2001; 7: 2285-2291.
48. Rini BI, Selk LM, Vogelzang NJ. Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions. Clin Cancer Res 1999; 5: 2766-2772.
49. Gleich LL, Gluckman JL, Armstrong S, Biddinger PW, Miller MA, Balakrishnan K et al. Alloantigen gene therapy for squamous cell carcinoma of the head and neck: results of a phase-1 trial. Arch Otolaryngol Head Neck Surg 1998; 124: 1097-1104.
50. Xu L, Pirollo KF, Chang EH. Transferrin-liposome-mediated p53 sensitization of squamous cell carcinoma of the head and neck to radiation in vitro. Hum Gene Ther 1997; 8: 467-475.
51. Barnard DL. Technology evaluation: Sch-58500, Canji. Curr Opin Mol Ther 2000; 2: 586-592.
52. Habib NA, Hodgson HJ, Lemoine N, Pignatelli M. A phase I/II study of hepatic artery infusion with wtp53-CMV-Ad in metastatic malignant liver tumours. Hum Gene Ther 1999; 10: 2019-2034.
53. Sauter ER, Ridge JA, Litwin S, Langer CJ. Pretreatment p53 protein expression correlates with decreased survival in patients with end-stage head and neck cancer. Clin Cancer Res 1995; 1: 1407-1412.
54. Matsubara H, Ochiai T. The protocol of clinical trial and basic experiments for esophageal cancer using gene transduction. Nippon Rinsho 2000; 58: 1935-1943.
55. Tait DL, Obermiller PS, Redlin-Frazier S, Jensen RA, Welcsh P, Dann J et al. A phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer. Clin Cancer Res 1997; 3: 1959-1968.
56. Xing X, Zhang S, Chang JY, Tucker SD, Chen H, Huang L et al. Safety study and characterization of E1A-liposome complex gene-delivery protocol in an ovarian cancer model. Gene Ther 1998; 5: 1538-1544.
57. Hortobagyi GN, Hung MC, Lopez-Berestein G. A Phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2/neu or epithelial ovarian cancer. Hum Gene Ther 1998; 9: 1775-1798.
58. Yoo GH, Hung MC, Lopez-Berestein G, LaFollette S, Ensley JF, Carey M et al. Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clin Cancer Res 2001; 7: 1237-1245.
59. Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB et al. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol 2001; 19: 3422-3433.
60. Fairbairn LJ, Rafferty JA, Lashford LS. Engineering drug resistance in human cells. Bone Marrow Transplant 2000; 25(Suppl2): S110-S113.
61. Abonour R, Williams DA, Einhorn L, Hall KM, Chen J, Coffman J et al. Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells. Nat Med 2000; 6: 652-658.
62. Bischoff JR, Kim DH, Williams A, Heise C, Horn S, Muna M et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373-376.
63. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kim DH. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997; 3: 639-645.
64. Habib NA, Sarraf CE, Mitry RR, Havlik R, Nicholls J, Kelly M et al. E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors. Hum Gene Ther 2001; 12: 219-226.
65. Kim D, Hermiston T, McCormick F. ONYX-015: clinical data are encouraging. Nat Med 1998; 4: 1341-1342.
66. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879-885.
67. Mulvihill S, Warren R, Venook A, Adler A, Randlev B, Heise C et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Ther 2001; 8: 308-315.
68. Fanslow WC, Sims JE, Sassenfeld H, Morrissey PJ, Gillis S, Dower SK et al. Regulation of alloreactivity in vivo by a soluble form of the interleukin-1 receptor. Science 1990; 248: 739-742.
69. Isobe M, Yagita H, Okumura K, Ihara A. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science 1992; 255: 1125-1127.
70. Roth C, Kourilsky P, Ojcius DM. Ly-49-independent inhibition of natural killer cell-mediated cytotoxicity by a soluble major histocompatibility complex class I molecule. Eur J Immunol 1994; 24: 2110-2114.
71. Zhang J, Cado D, Chen A, Kabra NH, Winoto A. Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1. Nature 1998; 392: 296-300.
72. Zwacka RM, Zhou W, Zhang Y, Darby CJ, Dudus L, Halldorson J et al. Redox gene therapy for ischemia/reperfusion injury of the liver reduces AP1 and NF-kappaB activation. Nat Med 1998; 4: 698-704.
73. Pattison JM, Krensky AM. New insights into mechanisms of allograft rejection. Am J Med Sci 1997; 313: 257-263.
74. Farhood A, McGuire GM, Manning AM, Miyasaka M, Smith CW, Jaeschke H. Intercellular adhesion molecule 1 (ICAM-1) expression and its role in neutrophil-induced ischemia-reperfusion injury in rat liver. J Leukoc Biol 1995; 57: 368-374.
75. Kelly KJ, Williams WW Jr, Colvin RB, Meehan SM, Springer TA, Gutierrez-Ramos JC et al. Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury. J Clin Invest 1996; 97: 1056-1063.
76. Drazan KE, Olthoff KM, Wu L, Shen XD, Gelman A, Shaked A. Adenovirus-mediated gene transfer in the transplant setting: early events after orthotopic transplantation of liver allografts expressing TGF-beta1. Transplantation 1996; 62: 1080-1084.
77. Qin L, Chavin KD, Ding Y, Tahara H, Favaro JP, Woodward JE et al. Retrovirus-mediated transfer of viral IL-10 gene prolongs murine cardiac allograft survival. J Immunol 1996; 156: 2316-2323.
78. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996; 14: 233-258.
79. Larsen CP, Elwood ET, Alexander DZ, Ritchie SC, Hendrix R, Tucker-Burden C et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434-438.
80. Olthoff KM, Judge TA, Gelman AE, da Shen X, Hancock WW, Turka LA et al. Adenovirus-mediated gene transfer into cold-preserved liver allografts: survival pattern and unresponsiveness following transduction with CTLA4Ig. Nat Med 1998; 4: 194-200.
81. Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, Falorni A et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002; 3: 1097-1101.
82. Lu L, Lee WC, Takayama T, Qian S, Gambotto A, Robbins PD et al. Genetic engineering of dendritic cells to express immunosuppressive molecules (viral IL-10, TGF-beta, and CTLA4Ig). J Leukoc Biol 1999; 66: 293-296.
83. Lee WC, Zhong C, Qian S, Wan Y, Gauldie J, Mi Z et al. Phenotype, function, and in vivo migration and survival of allogeneic dendritic cell progenitors genetically engineered to express TGF-beta. Transplantation 1998; 66: 1810-1817.
84. Tan PH, Beutelspacher S, Wang YH, McClure MO, Ritter MA, Lombardi G et al. Immunolipoplexes: an efficient, nonviral alternative for transfection of human dendritic cells with potential for clinical vaccination. Mol Ther 2005; 11: 790-800.
85. Lu L, Gambotto A, Lee WC, Qian S, Bonham CA, Robbins PD et al. Adenoviral delivery of CTLA4Ig into myeloid dendritic cells promotes their in vitro tolerogenicity and survival in allogeneic recipients. Gene Ther 1999; 6: 554-563.
86. Tan PH, Yates JB, Xue SA, Chan C, Jordan WJ, Harper JE et al. Creation of tolerogenic human DC via intracellular CTLA4: a novel strategy with potential in clinical immunosuppression. Blood 2005; (in press).
87. Nagata S. Fas ligand-induced apoptosis. Annu Rev Genet 1999; 33: 29-55.
88. Gainer AL, Suarez-Pinzon WL, Min WP, Swiston JR, Hancock-Friesen C, Korbutt GS et al. Improved survival of biolistically transfected mouse islet allografts expressing CTLA4-Ig or soluble Fas ligand. Transplantation 1998; 66: 194-199.
89. Kang SM, Schneider DB, Lin Z, Hanahan D, Dichek DA, Stock PG et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med 1997; 3: 738-743.
90. Hanabuchi S, Koyanagi M, Kawasaki A, Shinohara N, Matsuzawa A, Nishimura Y et al. Fas and its ligand in a general mechanism of T-cell-mediated cytotoxicity. Proc Natl Acad Sci U S A 1994; 91: 4930-4934.
91. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995; 81: 505-512.
92. Ray CA, Black RA, Kronheim SR, Greenstreet TA, Sleath PR, Salvesen GS et al. Viral inhibition of inflammation: cowpox virus encodes an inhibitor of the interleukin-1 beta converting enzyme. Cell 1992; 69: 597-604.
93. Yamabe K, Shimizu S, Kamiike W, Waguri S, Eguchi Y, Hasegawa J et al. Prevention of hypoxic liver cell necrosis by in vivo human bcl-2 gene transfection. Biochem Biophys Res Commun 1998; 243: 217-223.
94. Kondo S, Yin D, Morimura T, Oda Y, Kikuchi H, Takeuchi J. Transfection with a bcl-2 expression vector protects transplanted bone marrow from chemotherapy-induced myelosuppression. Cancer Res 1994; 54: 2928-2933.
95. Kohn DB, Hershfield MS, Carbonaro D, Shigeoka A, Brooks J, Smogorzewska EM et al. T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. Nat Med 1998; 4: 775-780.
96. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288: 669-672.
97. Schuening F, Longo WL, Atkinson ME, Zaboikin M, Kiem HP, Sanders J et al. Retrovirus-mediated transfer of the cDNA for human glucocerebrosidase into peripheral blood repopulating cells of patients with Gaucher's disease. Hum. Gene Ther 1997; 8: 2143-2160.
98. Malech HL, Maples PB, Whiting-Theobald N, Linton GF, Sekhsaria S, Vowells SJ et al. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci U S A 1997; 94: 12133-12138.
99. Liu JM, Kim S, Read EJ, Futaki M, Dokal I, Carter CS et al. Engraftment of hematopoietic progenitor cells transduced with the Fanconi anemia group C gene (FANCC). Hum Gene Ther 1999; 10: 2337-2346.
100. Rosengart TK, Lee LY, Patel SR, Sanborn TA, Parikh M, Bergman GW et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999; 100: 468-474.
101. Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, Maysky M et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998; 98: 2800-2804.
102. Laitinen M, Hartikainen J, Hiltunen MO, Eranen J, Kiviniemi M, Narvanen O et al. Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty. Hum Gene Ther 2000; 11: 263-270.
103. Rajagopalan S, Shah M, Luciano A, Crystal R, Nabel EG. Adenovirus-mediated gene transfer of VEGF(121) improves lower-extremity endothelial function and flow reserve. Circulation 2001; 104: 753-755.
104. Baumgartner I, Pieczek A, Manor O, Blair R, Kearney M, Walsh K et al. Constitutive expression of phVEGFl65 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998; 97: 1114-1123.
105. Isner JM, Baumgartner I, Rauh G, Schainfeld R, Blair R, Manor O et al. Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J Vasc Surg 1998; 28: 964-973.
106. Mann MJ, Whittemore AD, Donaldson MC, Belkin M, Conte MS, Polak JF et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet 1999; 354: 1493-1498.
107. Chung-Faye GA, Chen MJ, Green NK, Burton A, Anderson D, Mautner V et al. In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase. Gene Ther 2001; 8: 1547-1554.
108. Harrison LH Jr, Schwarzenberger PO, Byrne PS, Marrogi AJ, Kolls JK, McCarthy KE. Gene-modified PA1-STK cells home to tumor sites in patients with malignant pleural mesothelioma. Ann Thorac Surg 2000; 70: 407-411.
109. Lian JB, Niyibizi C. Gene therapy for genetic diseases of bone. Clin Orthop 2000; 379(Suppl): S159-S163.
110. Wang Q, Marini JC. Antisense oligodeoxynucleotides selectively suppress expression of the mutant alpha 2(I) collagen allele in type IV osteogenesis imperfecta fibroblasts. A molecular approach to therapeutics of dominant negative disorders. J Clin Invest 1996; 97: 448-454.
111. Gouze E, Ghivizzani SC, Palmer GD, Gouze JN, Robbins PD, Evans CH. Gene therapy for rheumatoid arthritis. Expert Opin Biol Ther 2001; 1: 971-978.
112. Bolon B, Carter C, Daris M, Morony S, Capparelli C, Hsieh A et al. Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis. Mol Ther 2001; 3: 197-205.
113. Eming SA, Morgan JR, Berger A. Gene therapy for tissue repair: approaches and prospects. Br J Plast Surg 1997; 50: 491-500.
114. Lamsam C, Fu FH, Robbins PD, Evans CH. Gene therapy in sports medicine. Sports Med 1998; 25: 73-77.
115. Chaudhary LR, Cheng SL, Avioli LV. Induction of early growth response-1 gene by interleukin-1 beta and tumor necrosis factor-alpha in normal human bone marrow stromal and osteoblastic cells: regulation by a protein kinase C inhibitor. Mol Cell Biochem 1996; 156: 69-77.
116. Benjamin R, Helman L, Meyers P, Reaman G. A phase I/II dose escalation and activity study of intravenous injections of OCaP1 for subjects with refractory osteosarcoma metastatic to lung. Hum Gene Ther 2001; 12: 1591-1593.
117. Niyibizi C, Baltzer A, Lattermann C, Oyama M, Whalen JD, Robbins PD et al. Potential role for gene therapy in the enhancement of fracture healing. Clin Orthop 1998; 355(Suppl): S148-S153.
118. Nakamura N, Timmermann SA, Hart DA, Kaneda Y, Shrive NG, Shino K et al. A comparison of in vivo gene delivery methods for antisense therapy in ligament healing. Gene Ther 1998; 5: 1455-1461.
119. Shenaq SM, Rabinovsky ED. Gene therapy for plastic and reconstructive surgery. Clin Plast Surg 1996; 23: 157-171.
120. Herman JR, Adler HL, Aguilar-Cordova E, Rojas-Martinez A, Woo S, Timme TL et al. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther 1999; 10: 1239-1249.
121. Pagliaro LC. Gene therapy for bladder cancer. World J Urol 2000; 18: 148-151.
122. Tani K, Nakazaki Y, Hase H, Takahashi K, Azuma M, Ohata J et al. Progress reports on immune gene therapy for stage IV renal cell cancer using lethally irradiated granulocyte-macrophage colony-stimulating factor-transduced autologous renal cancer cells. Cancer Chemother Pharmacol 2000; 46(Suppl): S73-S76.
123. Champion HC, Bivalacqua TJ, Hyman AL, Ignarro LJ, Hellstrom WJ, Kadowitz PJ. Gene transfer of endothelial nitric oxide synthase to the penis augments erectile responses in the aged rat. Proc Natl Acad Sci U S A 1999; 96: 11648-11652.
124. Belldegrun A, Tso CL, Zisman A, Naitoh J, Said J, Pantuck AJ et al. Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology. Hum Gene Ther 2001; 12: 883-892.
125. Koeneman KS, Kao C, Ko SC, Yang L, Wada Y, Kallmes DF et al. Osteocalcin-directed gene therapy for prostate-cancer bone metastasis. World J Urol 2000; 18: 102-110.
126. Logothetis CJ, Hossan E, Evans R, Pettaway CA, Steiner MS, Gringrich J et al. Ad5CMV-p53 intraprostatic gene therapy preceding radical prostatectomy (RP); an in vivo model for targeted therapy development. Proc Am Soc Clin Oncol 1999; 18: 313a (Abstract).
127. Doehn C, Jocham D. Technology evaluation: CN-706, Calydon Inc. Curr Opin Mol Ther 2000; 2: 703-708.
128. Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 1999; 59: 5160-5168.
129. Jacobs A, Voges J, Reszka R, Lercher M, Gossmann A, Kracht L et al. Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet 2001; 358: 727-729.
130. Klatzmann D, Valery CA, Bensimon G, Marro B, Boyer O, Mokhtari K et al. A phase I/II study of herpes simplex virus type 1 thymidine kinase 'suicide' gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum Gene Ther 1998; 9: 2595-2604.
131. Sandmair AM, Loimas S, Puranen P, Immonen A, Kossila M, Puranen M et al. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther 2000; 11: 2197-2205.
132. Eck SL, Alavi JB, Judy K, Phillips P, Alavi A, Hackney D et al. Treatment of recurrent or progressive malignant glioma with a recombinant adenovirus expressing human interferon-beta (H5.010CMVhIFN-beta): a phase I trial. Hum Gene Ther 2001; 12: 97-113.
133. Brenner MK, Heslop H, Krance R, Horowitz M, Strother D, Nuchtern J et al. Phase I study of chemokine and cytokine gene-modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma using an adenoviral vector. Hum Gene Ther 2000; 11: 1477-1488.
134. Okada H, Pollack IF, Lotze MT, Lunsford LD, Kondziolka D, Lieberman F et al. Gene therapy of malignant gliomas: a phase I study of IL-4-HSV-TK gene-modified autologous tumor to elicit an immune response. Hum Gene Ther 2000; 11: 637-653.
135. Andrews DW, Resnicoff M, Flanders AE, Kenyon L, Curtis M, Merli G et al. Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J Clin Oncol 2001; 19: 2189-2200.
136. Okada H, Pollack IF, Lieberman F, Lunsford LD, Kondziolka D, Schiff D et al. Gene therapy of malignant gliomas: a pilot study of vaccination with irradiated autologous glioma and dendritic cells admixed with IL-4 transduced fibroblasts to elicit an immune response. Hum Gene Ther 2001; 12: 575-595.
137. Beutler AS, Banck MS, Wedekind D, Hedrich HJ. Tumor gene therapy made easy: allogeneic major histocompatibility complex in the C6 rat glioma model. Hum Gene Ther 1999; 10: 95-101.
138. Gupta N. Current status of viral gene therapy for brain tumours. Expert Opin Investig Drugs 2000; 9: 713-726.
139. Abicht A, Lochmuller H. Technology evaluation: CRIB (CNTF delivery) CytoTherapeutics Inc. Curr Opin Mol Ther 1999; 1: 645-650.
140. Fraites TJ Jr, Schleissing MR, Shanely RA, Walter GA, Cloutier DA, Zolotukhin I et al. Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors. Mol Ther 2002; 5: 571-578.
141. Roth DA, Tawa NE Jr, O'Brien JM, Treco DA, Selden RF. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. N Engl J Med 2001; 344: 1735-1742.
142. Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW, Arruda VR et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003; 101: 2963-2972.
143. Hacein-Bey-Abina S, Fischer A, Cavazzana-Calvo M. Gene therapy of X-linked severe combined immunodeficiency. Int J Hematol 2002; 76: 295-298.
144. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348: 255-256.
145. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003; 80: 148-158.
146. Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000; 24: 257-261.
147. Arruda VR, Fields PA, Milner R, Wainwright L, De Miguel MP, Donovan PJ et al. Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males. Mol Ther 2001; 4: 586-592.
148. Rainov NG. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 2000; 11: 2389-2401.
149. National Institutes of Health. Database on Human Gene Therapy Trials (GeMCRIS). (http://www4.od.nih.gov/oba/rac/clinicaltrial.htm). [September 2005]